Although adoptive transfer of cytotoxic T lymphocytes (CTL) offer a promising cancer therapeutic direction, the generation of antigen-specific CTL from patients has faced difficulty in efficient expansion in ex vivo culture. To resolve this issue, several groups have proposed that induced pluripotent stem cell technology be applied for the expansion of antigen-specific CTL, which retain expression of the same T-cell receptor as original CTL. However, in these previous studies, the regenerated CTL are mostly of the CD8aa þ innate type and have less antigen-specific cytotoxic activity than primary CTL. Here we report that, by stimulating purified iPSC-derived CD4/CD8 double-positive cells with anti-CD3 antibody, T cells expressing CD8ab were generated and exhibited improved antigen-specific cytotoxicity compared with CD8aa þ CTL. Failure of CD8ab T-cell production using the previous method was found to be due to killing of doublepositive cells by the double-negative cells in the mixed cultures. We found that WT1 tumor antigen-specific CTL regenerated by this method prolonged the survival of mice bearing WT1-expressing leukemic cells. Implementation of our methods may offer a useful clinical tool. Cancer Res; 76(23); 6839-50. Ó2016 AACR.
Introduction
During the last several years, cancer immunotherapy using a variety of strategies has progressed remarkably, for example, blockade of inhibitory signals in the immune system (1-3), adoptive transfer of cytotoxic T lymphocytes (CTL; refs. [4] [5] [6] , transfer of T-cell receptor (TCR) genes (7) (8) (9) , etc. Although these achievements may suggest that CTLs present in cancer patients have the potential to cure them, researchers and clinicians have been facing a major obstacle in getting enough antigen-specific CTLs for therapy. Some groups have reported that tumor infiltrating lymphocytes (TIL) or tumor antigen specific CTLs can be efficiently expanded (10) (11) (12) (13) , but in general it is not so easy. This problem is mainly attributable to the nature of CTLs; they easily become exhausted or die during cultivation.
To solve this problem, we came to the idea of utilizing induced pluripotent stem cell (iPSC) technology for the cloning and expansion of CTLs. When iPSCs are established from antigenspecific T cells (T-iPSC), they should inherit rearranged TCR genes, and thus all T cells regenerated from T-iPSCs should express the same TCR. Because iPSC expansion in vitro is almost unlimited, it should be possible to obtain as many fresh CTLs as needed. In keeping with this idea, we have recently succeeded in regenerating MART1-specific CTLs from iPSCs originally derived from CTLs of a melanoma patient (14) . Other groups also have regenerated viral antigen-specific T cells (15, 16) , T cells expressing an invariant TCRs (17) (18) (19) , and T cells that were genetically engineered to express a so-called chimeric antigen receptor (CAR; ref. 20) .
None of the previous studies, however, showed whether these regenerated CTLs are as good as primary CTLs in terms of antigenspecific cytotoxic activity. Indeed, in the study using CAR-T-iPSCs, the authors stated that regenerated CTLs are phenotypically similar to gdT cells (20) .
Authentic CTLs are CD4 À CD8a þ CD8b þ (CD8ab heterodimer þ ). CD8aa type T cells represent a minor population in most lymphoid tissues but are one of the major populations in the mucosal tissues, where they are regarded as "innate type" T cells. Of note, the CD8aa homodimer does not function well as a TCR coreceptor, because it does not efficiently bind to MHC class I molecules (21) . Although regenerated CD8 T cells in the previous studies all seemed to be of the innate type, in this study we describe a novel yet simple method to generate CD8ab T cells and show that they are active against leukemia.
Materials and Methods

Study approval
This study was approved by the Institutional Review Board of the Graduate School of Medicine, Kyoto University (approval number: G761) and abided by the tenets of the Declaration of Helsinki. All specimens from healthy individuals and patients were collected after written informed consent was obtained.
Cell lines
Op9, OP9/DLL1, and 409B2 were purchased from RIKEN BRC. THP1 was purchased from ATCC. HL60, HEL, and KG1a were maintained in our department. OUN1 and MEG01 were gifts from Dr. Masaki Yasukawa (Ehime University, Ehime, Japan). K562 was a gift from Dr. Kiyotaka Kuzushima (Aichi Cancer Center, Aichi, Japan). C1R-A Ã 24:02 was a gift from Dr. Masafumi Takiguchi (Kumamoto University, Kumamoto, Japan). Upon receiving the cell lines, frozen stocks were prepared within one to five passages and new stocks were thawed frequently to keep the original condition. The cell lines were passaged for less than 3 months after receipt or resuscitation. They were also authenticated by morphology, growth rate, and surface phenotype, especially expression of HLA class I.
Differentiation of T-iPSCs to CD8ab single positive cells
T-iPSCs were differentiated to CD4/8 double-positive (DP) cells using the OP9 and OP9/DLL1 stromal cell coculture systems as described (14, 22, 23) , with slight modification. In brief, iPSC colonies were dissociated using trypsin (0.25%) and collagenase IV (1 mg/mL) and mechanically disrupted into small clumps by pipetting. About 600 iPSC clumps were collected and plated on gelatin precoated OP9 dishes filled with OP9 medium, that is, a-MEM (Invitrogen) with 20% FCS. On day 13, colonies were treated with collagenase Type IV (50 U/mL) and trypsin-EDTA (0.05%). Cells were plated in a OP9/DLL1 semiconfluent dish on OP9 medium containing hIL-7 (5 ng/mL), hFlt-3L (5 ng/mL), and Regeneration of CD8aa innate type T cells by the conventional method. A, Flow cytometric profiles of PBMC of a healthy volunteer before and after stimulation with LMP2 peptide pulsed LCLs, which were used as antigen-presenting cells. LMP2-specific CTLs were detected as the CD8a þ LMP2-tetramer þ fraction (boxed). B, In vitro cytotoxic assay of LMP2-specific CTLs from A against HLA-A Ã 24:02 þ THP1 cells pulsed with LMP2 peptide at different concentrations. E:T ratio, effector-to-target ratio. C, Photomicrograph of T-iPSCs; LMP2#1-1 established from the LMP2-specific CTLs. Scale bar, 500 mm. D, Flow cytometric profiles of cells generated from T-iPSCs; LMP2#1-1 at day 40 of culture. E, Flow cytometric profiles of cells generated from those shown in D after stimulation with CD3 Ab for 6 days. F, In vitro cytotoxic assay of regenerated CD8aa T cells against THP1 targets pulsed with LMP2 peptide at different concentrations. Representative of three independent experiments. G, Comparison of the cytotoxic activity between the original CTLs and the regenerated CD8aa T cells against THP1 targets at different concentrations of LMP2 peptide. The E:T ratio was fixed at 3: CD28  CCR7  ID3  FOXP1  FAS  PRDM1  LEF1  IFNG  KLRG1  ZEB2  KLF2  SELL  CD27  TCF7  TBX21  IL2RB   TIM3   ITK   GNLY  GZMB  CD3E   FAS   LCK  GZMA  PRF1  LAT  ZAP70  LAG3  CD8B  CD28  CTLA4  CD4  ITGA2  PDCD1  ITGA1  LTA  BCL11B   CD8A   ICAM1  FASLG  NOTCH1  TRAIL   HIF1B   SPI1  RORC  TOX2  SOX13  ID2  RUNX3  ETS1  IKZF1  TBX21  BATF  ZBTB16  EOMES  RUNX1  BCL6  FOXO1  TOX  FOXO3  AHR  FOXP1  ID3  PRDM1  BCL11B  NFIL3  GATA3  GFI1  HIF1A  TCF3 12 Value IL2RG   IL2  CCR3  IFNGR1  IL15RA  IFNG  IL21R  IL7R  CCR4  CCR7  CCR2  CCR1  CCR6  CXCR6  CCR5  TNF  IL2RA  CXCR4  IL4R  IL16  CCL3  CCL4  CXCR3  IL2RB  TGFB1   DNAM1   RORC  NCAM1  NCR2  FCGR3A  KIR2DL4  KIR2DS4  KIR2DL1  KIR2DL3  KIR3DL1  SOX13  KIR3DL2  KIR3DL3  NKG2D  NCR3 Violet and CFSE, respectively. A total of 10 5 cells of the DP and DN cell mixture at the indicated ratios were cultured with CD3 Ab (15 ng/mL). After 6 days, cells were analyzed by flow cytometer.
Transwell coculture of immature DP and DN cells
The transwell system was used for the detection of soluble mediator effects. Labeled DP and DN cells (5 Â 10 4 cells each) as above were seeded in the lower and upper compartments, respectively, of a 0.4 mm pore size transwell plate (Coaster), and cultured in the presence of CD3 Ab (15 ng/mL). In control wells, DP or DN cells (5 Â 10 4 cells) or their mixture (5 Â 10 4 cells each) were cultured with CD3 Ab. After 6 days, cells were analyzed by flow cytometer.
Cytotoxic assay of DN cells against DP cells
Labeled DP and DN cells as above were cocultured at the indicated ratio with or without CD3 Ab for 5 hours. Annexin V (BioLegend) and PI double-negative cells were considered as alive.
RNA sequencing and data analysis
Regenerated LMP2-specific CD8aa T cells and CD8ab T cells were isolated by FACS Aria III (BD Bioscience). Isolated peripheral blood CD8aa T cells (TCRab
, and gdT cells (TCRgd þ TCRab À ) were stimulated with CD3/28 stimulator (Milteny Biotec) for 7 days according to the manufacturer's instructions in the presence of hIL-7 (10 ng/mL) and hIL-15 (20 ng/mL). Total RNA was isolated using an RNeasy Plus Mini Kit (QIAGEN). Libraries for RNA sequence were prepared using NEBNext Ultra RNA Library Prep Kit for Illumina (New England Biolabs). Sequence alignment was performed using our in-house pipelines as previously described (24) . Fragments per kilobase of exon per million fragments mapped (FPKM) was calculated for Refseq genes and then log-transformed. The hierarchical clustering of gene expression data was performed using Pearson's dissimilarity as distance measure and centroid method for linkage. For this analysis, we removed genes with no or low expression (mean FPKM < 2), then identified the most variant 5% of genes (n ¼ 527). Multi Experiment Viewer software was used to generate heat maps and hierarchical clustering. GEO accession number is GSE 81975.
Statistical analysis
All data with error bars are presented as mean AE SD. Difference was assessed using paired t-test using Prism (GraphPad software). Values of P < 0.05 were considered significant.
Results
CD8 T cells induced by the conventional method are of the innate type, expressing a CD8aa homodimer
Latent membrane protein 2 (LMP2) is an Epstein-Barr virus (EBV)-encoded antigen that is considered as a good CTL target in EBV-related tumors (25, 26) . LMP2-specific CTLs, defined by LMP2 tetramer staining, from a healthy volunteer were expanded by stimulation with antigen-presenting cells loaded with LMP2 peptide (Fig. 1A) . After several weeks of expansion, these antigen-specific CTLs efficiently killed leukemic cells loaded with LMP2 peptide at 1 nmol/L concentration (Fig. 1B) .
For establishment of iPS cells from CTLs, we used SV40 Large T antigen (27, 28) in addition to Yamanaka factors to enhance the efficiency of reprogramming (Supplementary Fig. S1 ). For transduction of CTLs, we used Sendi virus vector, which has been shown to be safe because transferred genes as well as viral genes are not integrated into genome (29, 30) . By transducing these CTLs with Yamanaka factors and SV40, two clones of iPSC lines, LMP2#1-1 and LMP2#2-13, were established. Sendai virus vectors containing Yamanaka factors and SV40 were not detected in either of these clones, and expression profiles of various stem cell genes were indistinguishable from those of control iPSCs (Supplementary Fig. S2A and S2B ). Hereafter, we will focus on the clone LMP2#1-1 (Fig. 1C) . Expression of stem cell genes in the LMP2#1-1 cell line was confirmed by cytochemistry, it had a normal karyotype, and was pluripotent, as judged by teratoma formation ( Supplementary Fig. S2C-S2E ).
We then induced T cells from LMP2-T-iPSCs using the conventional method (14) . As has been reported, DP and DN cells expressed TCR on Day 40 (Fig. 1D ). Upon stimulation with CD3 Ab, CD8 T cells were generated after 6 days and were exclusively of the CD8aa type and LMP2-tetramer positive (Fig. 1E) . However, as much as 100 nmol/L peptide was required to induce efficient cytotoxic activity (Fig. 1F ), making these cells $100-fold less competent than primary CTLs (Fig. 1G) . However, the regenerated CTLs were able to efficiently kill K562 (Fig. 1H) , indicating that they have high Natural Killer (NK)-like cytotoxicity.
Isolated DP cells give rise to CD8ab T cells upon stimulation
We searched then for conditions in which CD8ab T cells could be induced. We found that when purified DP cells were stimulated with CD3 Ab, CD8SP cells were generated and they were mostly of CD8ab type ( Fig. 2A) . By contrast, purified DN cells gave rise to CD8aa T cells upon activation ( Fig. 2A and B) . The CD8ab T cells could also be efficiently generated from purified DP cells stimulated by autologous LCLs loaded with LMP2 peptide (Fig. 2C) , indicating that the absence of DN cells, rather than the stimulation method, is critical for the induction of CD8ab T cells.
To exclude the possibility that a preexisting small number of CD8ab cells were preferentially expanded, purified DP cells were labeled with Cell Trace Violet, and then stimulated ( Fig. 2D) . On day 2, DP cells started to downregulate CD4 without cell division, and then CD8ab cells were generated on day 4 with only one or two cell divisions, indicating that CD8SP cells were induced from DP cells.
DN cells kill DP cells upon stimulation
Thus, it seemed that DN cells might be exerting a suppressive effect on the generation of CD8ab T cells. To test this possibility, isolated DP and DN cells were mixed at various ratios before stimulation, and it was seen that DN cells at a one ninth ratio to DP cells almost completely suppressed the generation of CD8ab T cells (Fig. 3A-C) .
The possibility that DN cells suppress DP-SP development by secreting soluble factors is unlikely, because virtually no suppression of CD8ab T-cell generation was seen in a transwell experiment in which DP cells and DN cells were separated by a semipermeable membrane (Fig. 3D and E) . We then observed that the DP cells died as early as 5 hours after activation in cultures with a mixture of DN and DP cells, and that the frequency of live DP cells decreased along with an increase in the DN/DP ratio ( Fig. 3F-I ), indicating that activated DN cells directly kill DP cells. We further found that a significant proportion of DN cells expressed perforin and granzyme A prior to activation (Fig. 3J) . These results indicate that failure of DP cells to generate CD8ab T cells after activation is attributable to the direct cytotoxicity of DN cells against DP cells. The entire culture procedure and profiles of generated cells are depicted in Supplementary Fig. S3 .
Gene expression profiles of regenerated CD8ab T cells
We analyzed gene expression profiles of regenerated CD8ab T cells (r-CD8ab) in comparison with regenerated CD8aa T cells (r-CD8aa) and primary CD8ab and CD8aa T cells (p-CD8ab, pCD8aa), using RNA-seq. Not only surface molecules, for example, CD3, CD8a, CD8b, and CD28 but also intracellular functional molecules, for example, GZMA, GZMB, PRF1, LCK, and BCL11B were commonly expressed in r-CD8ab and p-CD8ab (Fig. 4A) . As to immune-checkpoint molecules, LAG3 was expressed in rCD8 cells but PDCD1 and HAVCR2 (Tim3) were very low in expression. The signature transcription factors of CD8 T cells including TBX21, RUNX3, GATA3, and IKZF1 were commonly expressed in all four groups, but ZBTB16 (PLZF), a representative transcription factor for innate type T cells (31) (32) (33) , was low in both r-CD8ab and p-CD8ab compared with both types of CD8aa cells (Fig. 4B) . Reflecting NK-like cytotoxicity of r-CD8aa, NK-related genes, for example, NCAM1, NCR1, NCR2, KLRC2, and KLRC3 were highly expressed in r-CD8aa. Although r-CD8ab also express some of them (KLRC2 and KLRC3), but others were not expressed (Fig. 4C) . However, r-CD8aa and r-CD8ab shared some common characteristics in terms of chemokine receptor expression, such as high CXCR3 and low CCR7 expression, which are reminiscent of effector CD8 T cells (Fig. 4D and E) . In global gene expression pattern, r-CD8ab were positioned closer to pCD8ab compared to r-CD8aa (Fig. 4F) . Taken together, these observations indicate that gene expression profiles of r-CD8ab resembled with that of p-CD8ab, although retaining some innate lymphocyte signature.
Regenerated CD8ab T cells exhibit antigen-specific cytotoxicity comparable to the original CTLs Regenerated CD8ab T cells killed antigen-loaded target cells at a 1 nmol/L peptide concentration (Fig. 5A) , and their antigen-specific cytotoxic activity was found to be slightly weaker than that of primary CTLs, but much stronger than that of regenerated CD8aa T cells (Fig. 5B, see Fig. 1G for comparison). Regenerated CD8ab T cells showed comparable potential to primary CTLs in producing IFNg, and produced IFNg and TNFa at more than 1 nmol/L concentration of peptide (Fig. 5C  and D) . NK-like cytotoxicity against K562 cells was weaker than regenerated CD8aa T cells (Fig. 5E) . These results collectively indicate that this novel method works well to regenerate functional CD8ab T cells. Another LMP2-specific T-iPSC clone #2-13 also differentiated to CD8ab T cells (Fig. 5E ) and exhibited peptide-specific cytotoxicity slightly weaker than the original CTLs (Fig. 5F ).
Regeneration of WT1-specific CTLs
We then decided to apply this method against acute myeloid leukemia (AML) cells expressing WT1 antigen, a cancertestis antigen broadly expressed in various types of solid tumors as well as in leukemia (34, 35) . We firstly induced WT1-specific CTLs from a healthy volunteer by using WT1 peptide (Fig. 6A ) and measured their cytotoxic activity (Fig. 6B) . We then produced iPSCs from these CTLs, and a total of three lines were established ( Supplementary Fig. S4 and Supplementary Table S1 ). Hereafter we will show the data using clone WT1#3-3. Regenerated cells were of the CD8ab type and WT1-tetramer positive (Fig. 6C) , and the sequence of the TCR genes in this clone was determined (Supplementary  Table S1 ).
We then expanded CD8 T cells by stimulating with an autologous B LCL carrying WT1 peptide, or with a CD3 Ab, and a six-to eight-fold expansion was seen during 1 week in both cases (Fig.  6D) . We decided to use LCL for further studies because they seemed slightly more efficient. During 6 to 8 weeks' culture, CD8 T cells were expanded by $10,000 fold (Fig. 6E) , changing their surface phenotype from a na€ ve to an effector/memory profile (Fig. 6F) . Regenerated CD8 T cells showed the same antigenspecific cytotoxic activity as the original CTLs ( Fig. 6G and H) .
Regenerated WT1-specific CTLs have cytotoxicity against leukemia cells
Regenerated WT1-CTLs also efficiently killed THP1 and HL60 cells, HLA-matched AML cell lines expressing endogenous WT1 protein (Fig. 7A) . The cytotoxic activity was almost completely eliminated by adding a blocking Ab against HLA (Continued.) Beginning at day 1, PBS or 5 Â 10 6 r-CD8ab WT1#3-3 were injected intraperitoneally into tumor-bearing mice every week for 4 weeks. hIL-2 and hIL-7 were injected intraperitoneally three times a week. E, Flow cytometric profiles of peripheral blood from control or CTL-treated mice. CD33 versus CD8 profiles gated on human CD45 positive cells are shown. HL60 and inoculated CTLs were detected as the human CD33 þ or CD8 þ fraction. Representative of three independent experiments. F, A Kaplan-Meier curve depicting the percent survival of the experimental and control groups is shown (n ¼ 15). Accumulation of three independent experiments. P < 0.05 by the log-rank test. G, Percentage of resident regenerated CTLs in indicated samples from NOG mice inoculated with r-CD8ab WT1#3-3 6 months before (n ¼ 7). NOG mice bearing no leukemia cells were inoculated with 5 Â 10 6 r-CD8ab WT1#3-3 and cytokines intraperitoneally in the same manner as shown in D. Each dot shows the data from each mouse.
class I, indicating that the killing was MHC restricted and dependent on TCR-MHC binding. Other AML cell lines OUN1 and MEG01 were also killed, but the cytotoxic activity was only partially suppressed by HLA blocking Ab, suggesting that they were also killed by NK-like cytotoxicity (Fig. 7B) (Fig. 7C) . Finally, we examined CTL activity in vivo in a xenograft model. NOD.Cg-Prkdcscid Il2rgtm1Sug/Jic (NOG) mice inoculated with HL60 cells followed by administration of regenerated CTLs (Fig.  7D) . Although leukemia cells expressing human CD33 were detected from all the control mice, inoculated regenerated CTLs were present in peripheral blood of all the treated mice (Fig. 7E) . The CTL treated mice showed significantly longer survival compared with control mice (Fig. 7F) .
Regenerated WT1-specific CTLs are safe
To test the safety of transfused regenerated CTLs, we did long-term observation in vivo. NOG mice bearing no leukemic cells were inoculated with regenerated CTLs in the same manner as in xenograft model (Fig. 1D) , and observed for 6 months. During observation period, no mice showed diarrhea or body weight loss. After 6 months, all mice were dissected, and mononuclear cells in bone marrow, spleen, and peripheral blood were analyzed. Small amount of regenerated CTLs were detected from spleen and bone marrow of some mice (Fig. 7G) . No mice suffered from tumor derived from regenerated CTLs. We also did not see any sign of tissue damage caused by transferred CTLs.
Discussion
Many groups have been struggling to produce CD8ab type T cells from T-iPSCs, but the critical method described here turned out to be rather simple, simply include a DP cell purification step before stimulation. Our results can be summarized as three points: upon TCR stimulation, (i) DP cells give rise to CD8ab T cells, (ii) DN cells immediately kill DP cells, (iii) DN cells give rise to CD8aa T cells. For the first point, the alternative ligand model of thymic selection may provide the explanation. According to this model, DP cells positively selected in the cortex by peptides specifically expressed there can survive in the medulla because they do not encounter the same peptide; thus, the agonist peptide can induce positive selection in the cortex (36, 37) . It may be that our culture system reproduces such a cortical, positively selecting microenvironment. As to the second point, we have shown that DN cells already contain mature cells (Fig. 3J) , although they do not kill other cells unless activated further via their TCR. It seems likely that DN cells kill DP cells by direct NK-like cytotoxicity; however, it remains to be studied what the target molecules are in this killing. As to the third point, in our system, the TCR is expressed at the DN stage ( Supplementary Fig. S3C ). When these cells are activated, they may undergo a developmental program toward gdT cells, because it is known that the DN cell fate decision is based on TCR signaling strength. DN cells take the gdT cell fate upon receiving a strong TCR signal via the gdTCR, whereas they take the abT cell fate when there is a weak signal via the preTCR (38, 39) . This model is also in line with previous reports showing that DN cells expressing a transgenic abTCR at the DN stage come to exhibit a gdT cell-like phenotype (40) .
Regenerated CD8ab T cells showed antigen-specific cytotoxicity slightly less, but nearly comparable to primary CD8ab T cells (Supplementary Table S2 ). This is a marked improvement compared to regenerated CD8aa T cells and might partly be explained because the CD8ab heterodimer binds to MHC class I and thus functions as a co-receptor to induce lck signaling, whereas the CD8aa homodimer does not. Gene expression profiles also showed that regenerated CD8ab T cells are closer to primary CD8ab T cells, although still retaining some phenotypic features of innate type T cells. As activated T cells express some NK activation receptors and signal molecules like NKG2D, NKp30, DAP12, and so on (41-43), it is not surprising that these regenerated CTLs cultured in vitro also express such NK-associated molecules and possess NK-like cytotoxic potential.
There is growing evidence that na€ ve T cells, stem cell memory T cells (T SCM ), or central memory T cells (T CM ) are superior as source of adoptive T-cell transfer for tumor immunotherapy (44) (45) (46) (47) . In terms of surface markers, regenerated CD8ab T cells expressing low CCR7 and high CXCR3 are considered as effector phenotype T cells, although we are using IL21 to inhibit terminal differentiation (5, 48) . Nevertheless, our culture method has advantages that the regenerated CD8ab T cells can be expanded more than 10,000 fold by repeated TCR stimulation while retaining comparable TCR-specific cytotoxic potential. Furthermore, it was reported to be hard to evaluate in vitro cultured CTLs just based on their surface markers with regard to the point whether they are terminally differentiated or not (49) . In addition, at present, it is also difficult to appropriately address this issue in vivo in xenograft model, because microenvironments in immune system of mouse xenograft model are so far from physiological situation in human. In case of murine CTLs regenerated from T-iPSCs, it was recently shown that the regenerated CTLs exhibited memory response in vivo in mice bearing syngeneic tumor (50) .
One may concern about the safety of regenerated CTLs is tumorigenecity after administration. Although we use SV40 large T antigen to establish T-iPSCs, we confirmed that SV40 was completely deleted from all the iPSCs. Also we examined the long-term safety in transfused mice, and confirmed all the mice were free of tumor derived from regenerated CTLs.
Another concern about safety is off-target specificity. In our method almost all the regenerated CD8ab T cells after expansion by LCL pulsed with cognate peptide retain the same TCR detected as tetramer positive cells (Fig. 2C, 5F , 6C, 6F). To be exact, this is not the case at the DP stage, where RAG1 and RAG2 genes are expressed and secondly rearrangement in TCR alpha chain gene may occur. Indeed, a part of the CD8ab T cells just regenerated by TCR stimulation have lost specificity for original epitope, resulting in the formation of negative population in tetramer staining ( Supplementary Fig. S3E, top right) . However, these cells can be eliminated during expansion by LCL pulsed with cognate peptide (Supplementary Fig. S3E , bottom right). We actually did not see any sign of Graft-versus-Host reaction in the mice inoculated with regenerated CTLs (Fig. 7G) . In addition, it is also possible to completely ensure clonality by deleting RAG1 or RAG2 gene in T-iPSCs using genome editing technology.
In this method starting from 10 4 T-iPSCs in one 10-cm culture dish, we can eventually obtain 10 9 to 10 10 regenerated CD8ab T cells in one round culture, which could be sufficient for one transfusion to a patient, thus providing a strong rationale for clinical application of this strategy. We have established antigen-specific T-iPSCs from healthy volunteers, making an allogeneic approach possible. In such an allogeneic setting, it would be preferable to produce T-iPSCs from an HLAhaplotype homozygous donor, because regenerated CTLs could then be used for HLA-haplotype heterozygous patients. In such a strategy, "Off the shelf" T-cell drug would come true by generating CD8ab T cells in advance and preserving as frozen stocks.
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